MEK1 and MEK2 inhibitors and cancer therapy

the long and winding road

Christopher J. Caunt, Matthew J. Sale, Paul D. Smith, Simon J. Cook

Research output: Contribution to journalLiterature review

181 Citations (Scopus)

Abstract

The role of the ERK signalling pathway in cancer is thought to be most prominent in tumours in which mutations in the receptor tyrosine kinases RAS, BRAF, CRAF, MEK1 or MEK2 drive growth factor-independent ERK1 and ERK2 activation and thence inappropriate cell proliferation and survival. New drugs that inhibit RAF or MEK1 and MEK2 have recently been approved or are currently undergoing late-stage clinical evaluation. In this Review, we consider the ERK pathway, focusing particularly on the role of MEK1 and MEK2, the ‘gatekeepers’ of ERK1/2 activity. We discuss their validation as drug targets, the merits of targeting MEK1 and MEK2 versus BRAF and the mechanisms of action of different inhibitors of MEK1 and MEK2. We also consider how some of the systems-level properties (intrapathway regulatory loops and wider signalling network connections) of the ERK pathway present a challenge for the success of MEK1 and MEK2 inhibitors, discuss mechanisms of resistance to these inhibitors, and review their clinical progress.
Original languageEnglish
Pages (from-to)577–592
Number of pages16
JournalNature Reviews Cancer
Volume15
Issue number10
Early online date24 Sep 2015
DOIs
Publication statusPublished - Oct 2015

Fingerprint

MAP Kinase Signaling System
Neoplasms
Receptor Protein-Tyrosine Kinases
Pharmaceutical Preparations
Cell Survival
Intercellular Signaling Peptides and Proteins
Therapeutics
Cell Proliferation
Mutation

Cite this

Caunt, C. J., Sale, M. J., Smith, P. D., & Cook, S. J. (2015). MEK1 and MEK2 inhibitors and cancer therapy: the long and winding road. Nature Reviews Cancer, 15(10), 577–592. https://doi.org/10.1038/nrc4000

MEK1 and MEK2 inhibitors and cancer therapy : the long and winding road. / Caunt, Christopher J. ; Sale, Matthew J.; Smith, Paul D.; Cook, Simon J.

In: Nature Reviews Cancer, Vol. 15, No. 10, 10.2015, p. 577–592.

Research output: Contribution to journalLiterature review

Caunt, CJ, Sale, MJ, Smith, PD & Cook, SJ 2015, 'MEK1 and MEK2 inhibitors and cancer therapy: the long and winding road', Nature Reviews Cancer, vol. 15, no. 10, pp. 577–592. https://doi.org/10.1038/nrc4000
Caunt, Christopher J. ; Sale, Matthew J. ; Smith, Paul D. ; Cook, Simon J. / MEK1 and MEK2 inhibitors and cancer therapy : the long and winding road. In: Nature Reviews Cancer. 2015 ; Vol. 15, No. 10. pp. 577–592.
@article{3cda3bf02b074c99b81593c2262c5d2d,
title = "MEK1 and MEK2 inhibitors and cancer therapy: the long and winding road",
abstract = "The role of the ERK signalling pathway in cancer is thought to be most prominent in tumours in which mutations in the receptor tyrosine kinases RAS, BRAF, CRAF, MEK1 or MEK2 drive growth factor-independent ERK1 and ERK2 activation and thence inappropriate cell proliferation and survival. New drugs that inhibit RAF or MEK1 and MEK2 have recently been approved or are currently undergoing late-stage clinical evaluation. In this Review, we consider the ERK pathway, focusing particularly on the role of MEK1 and MEK2, the ‘gatekeepers’ of ERK1/2 activity. We discuss their validation as drug targets, the merits of targeting MEK1 and MEK2 versus BRAF and the mechanisms of action of different inhibitors of MEK1 and MEK2. We also consider how some of the systems-level properties (intrapathway regulatory loops and wider signalling network connections) of the ERK pathway present a challenge for the success of MEK1 and MEK2 inhibitors, discuss mechanisms of resistance to these inhibitors, and review their clinical progress.",
author = "Caunt, {Christopher J.} and Sale, {Matthew J.} and Smith, {Paul D.} and Cook, {Simon J.}",
year = "2015",
month = "10",
doi = "10.1038/nrc4000",
language = "English",
volume = "15",
pages = "577–592",
journal = "Nature Reviews Cancer",
issn = "1474-175X",
publisher = "Nature Research",
number = "10",

}

TY - JOUR

T1 - MEK1 and MEK2 inhibitors and cancer therapy

T2 - the long and winding road

AU - Caunt, Christopher J.

AU - Sale, Matthew J.

AU - Smith, Paul D.

AU - Cook, Simon J.

PY - 2015/10

Y1 - 2015/10

N2 - The role of the ERK signalling pathway in cancer is thought to be most prominent in tumours in which mutations in the receptor tyrosine kinases RAS, BRAF, CRAF, MEK1 or MEK2 drive growth factor-independent ERK1 and ERK2 activation and thence inappropriate cell proliferation and survival. New drugs that inhibit RAF or MEK1 and MEK2 have recently been approved or are currently undergoing late-stage clinical evaluation. In this Review, we consider the ERK pathway, focusing particularly on the role of MEK1 and MEK2, the ‘gatekeepers’ of ERK1/2 activity. We discuss their validation as drug targets, the merits of targeting MEK1 and MEK2 versus BRAF and the mechanisms of action of different inhibitors of MEK1 and MEK2. We also consider how some of the systems-level properties (intrapathway regulatory loops and wider signalling network connections) of the ERK pathway present a challenge for the success of MEK1 and MEK2 inhibitors, discuss mechanisms of resistance to these inhibitors, and review their clinical progress.

AB - The role of the ERK signalling pathway in cancer is thought to be most prominent in tumours in which mutations in the receptor tyrosine kinases RAS, BRAF, CRAF, MEK1 or MEK2 drive growth factor-independent ERK1 and ERK2 activation and thence inappropriate cell proliferation and survival. New drugs that inhibit RAF or MEK1 and MEK2 have recently been approved or are currently undergoing late-stage clinical evaluation. In this Review, we consider the ERK pathway, focusing particularly on the role of MEK1 and MEK2, the ‘gatekeepers’ of ERK1/2 activity. We discuss their validation as drug targets, the merits of targeting MEK1 and MEK2 versus BRAF and the mechanisms of action of different inhibitors of MEK1 and MEK2. We also consider how some of the systems-level properties (intrapathway regulatory loops and wider signalling network connections) of the ERK pathway present a challenge for the success of MEK1 and MEK2 inhibitors, discuss mechanisms of resistance to these inhibitors, and review their clinical progress.

UR - http://dx.doi.org/10.1038/nrc4000

UR - http://www.nature.com/nrc/journal/v15/n10/abs/nrc4000.html

U2 - 10.1038/nrc4000

DO - 10.1038/nrc4000

M3 - Literature review

VL - 15

SP - 577

EP - 592

JO - Nature Reviews Cancer

JF - Nature Reviews Cancer

SN - 1474-175X

IS - 10

ER -